CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss) attributable to BioTime, Inc.	$ 38,647	$ (33,567)
Net loss allocable to non-controlling interest	(12,286)	(7,762)
Adjustments to reconcile net income (loss) attributable to BioTime, Inc. to net cash used in operating activities:
Gain on deconsolidation of Asterias (Note 4)	(49,048)	0
Unrealized gain on equity method investment in Asterias at fair value	(26,532)	0
Depreciation expense	996	776
Amortization of intangible assets	2,935	3,942
Amortization of deferred grant income	1,496	1,869
Amortization of deferred license fees	85	85
Amortization of prepaid rent in common stock	0	63
Stock-based compensation	6,303	7,189
Subsidiary shareholder expense for subsidiary warrants	3,125	0
Amortization of discount on related party convertible debt	264	182
BioTime's share of losses in equity method investment in Ascendance	1,189	0
Deferred income tax benefit	0	(3,395)
Contingently issuable subsidiary warrants in lieu of investor relations expenses	0	65
Bad debt expense	802	0
Changes in operating assets and liabilities:
Accounts and grants receivable, net	(955)	98
Inventory	0	6
Prepaid expenses and other current assets	(1,013)	(621)
Other long term assets	0	(100)
Accounts payable and accrued liabilities	367	512
Accrued interest on related party convertible debt	0	14
Other liabilities	33	(9)
Deferred rent liabilities	95	(2)
Lease liability	156	(12)
Deferred revenues	(133)	70
Net cash used in operating activities	(33,474)	(30,597)
CASH FLOWS FROM INVESTING ACTIVITIES:
Deconsolidation of Asterias cash and cash equivalents (Note 3)	(8,376)	0
Purchase of equipment and other assets	(1,860)	(514)
Payments on construction in progress	(278)	(3,830)
Loan receivable	0	(500)
Security deposit received, net	34	(9)
Net cash used in investing activities	(10,480)	(4,853)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from sales of BioTime common stock in public offering	20,125	0
Discounts and fees paid for sale of BioTime common stock in public offering	(1,515)	0
Proceeds from exercises of stock options	2,015	621
Proceeds from exercise of warrants	0	19
Proceeds from issuance of common shares	0	8,578
Proceeds from sale of treasury stock and subsidiary warrants	0	11,700
Proceeds from sale of treasury shares	0	576
Reimbursement from landlord on construction in progress	451	2,564
Proceeds from issuance of related party convertible debt	1,150	188
Repayment of capital lease obligation	(104)	(31)
Proceeds from sale of common shares and warrants of subsidiary	10,721	11,586
Fees paid on sale of common shares and warrants of subsidiary	(904)	(597)
Proceeds from exercise of subsidiary stock options	0	27
Net cash provided by financing activities	31,939	35,231
Effect of exchange rate changes on cash and cash equivalents	237	110
NET CHANGE IN CASH AND CASH EQUIVALENTS:	(11,778)	(109)
CASH AND CASH EQUIVALENTS:
At beginning of the period	42,229	29,487
At end of the period	$ 30,451	$ 29,378